Monte Rosa Therapeutics GLUE Stock
Monte Rosa Therapeutics Price Chart
Monte Rosa Therapeutics GLUE Financial and Trading Overview
| Monte Rosa Therapeutics stock price | 7.21 USD |
| Previous Close | 6.59 USD |
| Open | 6.62 USD |
| Bid | 0 USD x 1100 |
| Ask | 0 USD x 1100 |
| Day's Range | 6.53 - 7.48 USD |
| 52 Week Range | 4.4 - 12.62 USD |
| Volume | 105.77K USD |
| Avg. Volume | 199.88K USD |
| Market Cap | 364.95M USD |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.63 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 19.63 USD |
GLUE Valuation Measures
| Enterprise Value | 139.28M USD |
| Trailing P/E | N/A |
| Forward P/E | -2.6205673 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 1.4965572 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -1.178 |
Trading Information
Monte Rosa Therapeutics Stock Price History
| Beta (5Y Monthly) | N/A |
| 52-Week Change | 7.25% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 12.62 USD |
| 52 Week Low | 4.4 USD |
| 50-Day Moving Average | 6.3 USD |
| 200-Day Moving Average | 7.36 USD |
GLUE Share Statistics
| Avg. Volume (3 month) | 199.88K USD |
| Avg. Daily Volume (10-Days) | 197.48K USD |
| Shares Outstanding | 49.38M |
| Float | 25.07M |
| Short Ratio | 11.92 |
| % Held by Insiders | 0.84% |
| % Held by Institutions | 84.03% |
| Shares Short | 2.29M |
| Short % of Float | 8.75% |
| Short % of Shares Outstanding | 4.63% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -23.34% |
| Return on Equity (ttm) | -40.94% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -118198000 USD |
| Net Income Avi to Common (ttm) | -116607000 USD |
| Diluted EPS (ttm) | -2.34 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 231.73M USD |
| Total Cash Per Share (mrq) | 4.7 USD |
| Total Debt (mrq) | 46.17M USD |
| Total Debt/Equity (mrq) | 18.94 USD |
| Current Ratio (mrq) | 11.726 |
| Book Value Per Share (mrq) | 4.938 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -88468000 USD |
| Levered Free Cash Flow (ttm) | -78298128 USD |
Profile of Monte Rosa Therapeutics
| Country | United States |
| State | MA |
| City | Boston |
| Address | 645 Summer Street |
| ZIP | 02210 |
| Phone | 617 949 2643 |
| Website | https://www.monterosatx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 133 |
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops an orally bioavailable molecular glue degrader for GSPT1, a a translation termination factor for the treatment of Myc-driven cancers. It also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as gout and Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and a therapeutically-relevant protein in hemoglobinopathies. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.
Q&A For Monte Rosa Therapeutics Stock
What is a current GLUE stock price?
Monte Rosa Therapeutics GLUE stock price today per share is 7.21 USD.
How to purchase Monte Rosa Therapeutics stock?
You can buy GLUE shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Monte Rosa Therapeutics?
The stock symbol or ticker of Monte Rosa Therapeutics is GLUE.
Which industry does the Monte Rosa Therapeutics company belong to?
The Monte Rosa Therapeutics industry is Biotechnology.
How many shares does Monte Rosa Therapeutics have in circulation?
The max supply of Monte Rosa Therapeutics shares is 50.15M.
What is Monte Rosa Therapeutics Price to Earnings Ratio (PE Ratio)?
Monte Rosa Therapeutics PE Ratio is now.
What was Monte Rosa Therapeutics earnings per share over the trailing 12 months (TTM)?
Monte Rosa Therapeutics EPS is -2.63 USD over the trailing 12 months.
Which sector does the Monte Rosa Therapeutics company belong to?
The Monte Rosa Therapeutics sector is Healthcare.
Monte Rosa Therapeutics GLUE included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ Global Select Market Com NQGS | 7876.03 USD — |
-1.61
|
— — | 7852.08 USD — | 7955.84 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4195.13 USD — |
-2.14
|
— — | 4174.1 USD — | 4266.29 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
| Stlmt ID NASDAQ Biotechnology NBX | 4604.4 USD — |
-2.98
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
- {{ link.label }} {{link}}